Aug 5, 2021 · Teva issued a press release, announcing the “tentative approval . . . for Carvedilol Tablets” and stating that “Carvedilol Tablets are the AB-rated generic equivalent of GlaxoSmithKline’s Coreg® Tablets and are indicated for treatment of …

Mar 29, 2018 · So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough evidence to show...

May 15, 2023 · The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart...

May 24, 2023 · GSK’s Coreg method-of-use patent was approved under the use code “decreasing mortality caused by congestive heart failure” when administered in daily doses for more than six months in concert with an ACE inhibitor, digoxin, and/or a diuretic.

Aug 6, 2021 · By a 2-1 vote, a U.S. Federal Circuit appeals panel ruled that Teva infringed a GSK patent by urging doctors to prescribe its generic version of Coreg for congestive heart failure, a use that was...

May 15, 2023 · Teva’s bid to have the Supreme Court hear its case—and potentially reverse a $235 million loss to GSK—has fallen on deaf ears, according to an order from the High Court issued Monday.

Aug 5, 2021 · The U.S. Court of Appeals for the Federal Circuit ruled to reinstate GlaxoSmithKline's $235 million jury win against Teva for its infringement of a patent related to the heart drug Coreg for...

Aug 17, 2021 · Teva filed an abbreviated new drug application (ANDA) with the FDA to manufacture a generic version of Coreg, and sought approval under section viii 5 for a label that carved out GSK’s patented indication for treatment of CHF. By this time, composition of matter patents for Coreg had expired.

The first two indications in GSK’s label for COREG were: (i) treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization; and (ii) to reduce cardiovascular mortality in clinically ...

Teva Pharmaceuticals has urged a Delaware federal judge to reject GlaxoSmithKline's request to enhance a $235 million infringement award over a skinny label version of GSK's cardiovascular...